<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04467151</url>
  </required_header>
  <id_info>
    <org_study_id>HS-20-00516</org_study_id>
    <nct_id>NCT04467151</nct_id>
  </id_info>
  <brief_title>Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial of Anti-SARS-CoV-2 Plasma in Hospitalized Non-ICU Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kashif Khan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of the administration of
      anti-SARS-CoV-2 convalescent plasma in COVID-19 patients who are sick enough to warrant
      hospitalization, but not yet admitted to the ICU (prior to the onset of overwhelming disease
      including a systemic inflammatory response, sepsis, and/or ARDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled trial to evaluate the safety and
      efficacy of anti-SARS-CoV-2 convalescent plasma in COVID-19 patients.

      After confirmation of COVID-19, patients that meet the eligibility requirement and provide
      informed consent will be randomized in a 2:1 ratio to anti-SARS-CoV-2 convalescent plasma (1
      unit of approximately 250 ml) or placebo (1 unit albumin 5%, approximately 250 ml). We will
      evaluate the ability of anti-SARS-CoV-2 convalescent plasma vs. placebo control to decrease
      disease progression (measured by the WHO Ordinal Scale for Clinical Improvement) during the
      28 days following administration to hospitalized, non-ICU patients. If patient is discharged
      from the hospital prior to Day 28, Day 28 assessment will be by phone.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease progression measured by WHO scale</measure>
    <time_frame>Day 0 through Day 28 (or hospital discharge)</time_frame>
    <description>Disease progression from the state at randomization (with a &quot;3&quot; or &quot;4&quot; on the WHO Ordinal Scale for Clinical Improvement) to requiring invasive mechanical ventilation (which is &quot;6&quot; or greater on the WHO scale) during the study period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of maximum WHO score per group</measure>
    <time_frame>Day 0 through Day 28 (or hospital discharge)</time_frame>
    <description>Comparison of the number of participants reaching a maximum daily WHO score of 5, 7, and 8 during the study period per group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of decrease of median and maximum WHO score per group</measure>
    <time_frame>Day 0 through Day 28 (or hospital discharge)</time_frame>
    <description>Comparison of the median and maximum daily WHO scores during the study period per group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of time to clinical improvement per group</measure>
    <time_frame>Day 0 through Day 28 (or hospital discharge)</time_frame>
    <description>Comparison of time to clinical improvement, defined as time between randomization and time to improvement (WHO Ordinal Scale &quot;2&quot; first reached for at least 1 day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of time to reach score of &quot;6&quot; or greater on the WHO scale</measure>
    <time_frame>Day 0 through Day 28 (or hospital discharge)</time_frame>
    <description>Evaluate the time to reach score of at least 6 within 28 days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of hospital length of stay per group</measure>
    <time_frame>Day 0 through Day 28 (or hospital discharge)</time_frame>
    <description>Evaluate number of days hospitalized</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of ICU length of stay per group</measure>
    <time_frame>Day 0 through Day 28 (or hospital discharge)</time_frame>
    <description>Evaluate number of hours in the ICU</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>anti-SARS-CoV-2 plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive one dose (250-300ml) of anti-SARS-CoV-2 convalescent plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive one dose (250-300ml) of placebo (albumin 5%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-SARS-CoV-2 plasma</intervention_name>
    <description>Administration of anti-SARS-CoV-2 convalescent plasma</description>
    <arm_group_label>anti-SARS-CoV-2 plasma</arm_group_label>
    <other_name>Convalescent Plasma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of placebo (albumin 5%)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Albumin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 years of age

          -  Hospitalized with COVID-19-related acute respiratory symptoms

          -  Initial COVID-19 severity status on the WHO Ordinal Scale for Clinical Improvement = 3
             (&quot;Hospitalized, no oxygen therapy) or 4 (&quot;Hospitalized, on oxygen by mask or nasal
             prongs&quot;)

          -  Laboratory-confirmed COVID-19

          -  First signs of infection occurring no more than 14 days prior to enrollment

        Exclusion Criteria:

          -  Receipt of pooled immunoglobulin in the past 30 days

          -  Contraindication to transfusion or history of prior reactions to transfusion blood
             products

          -  Admission to intensive care unit at any point during hospital course prior to
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kashif T Khan, MD, SM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keck School of Medicine of University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane F McIntee, MS</last_name>
    <phone>323-409-5814</phone>
    <email>mcintee@usc.edu</email>
  </overall_contact>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.</citation>
    <PMID>32167489</PMID>
  </reference>
  <reference>
    <citation>Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995 Jul;21(1):150-61. Review.</citation>
    <PMID>7578724</PMID>
  </reference>
  <reference>
    <citation>Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004 Sep;2(9):695-703. Review.</citation>
    <PMID>15372080</PMID>
  </reference>
  <reference>
    <citation>Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol. 2003 Oct;1(1):17-24. Review.</citation>
    <PMID>15040176</PMID>
  </reference>
  <reference>
    <citation>Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 1994 Aug;38(8):1695-702. Review.</citation>
    <PMID>7985997</PMID>
  </reference>
  <reference>
    <citation>Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6.</citation>
    <PMID>15616839</PMID>
  </reference>
  <reference>
    <citation>Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16. Review.</citation>
    <PMID>25030060</PMID>
  </reference>
  <reference>
    <citation>Ko JH, Seok H, Cho SY, Ha YE, Baek JY, Kim SH, Kim YJ, Park JK, Chung CR, Kang ES, Cho D, Müller MA, Drosten C, Kang CI, Chung DR, Song JH, Peck KR. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018;23(7):617-622. doi: 10.3851/IMP3243. Epub 2018 Jun 20.</citation>
    <PMID>29923831</PMID>
  </reference>
  <reference>
    <citation>Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, Al-Dawood A, Al-Qahtani S, Al-Omari A, Al-Hameed F, Hayden FG, Fowler R, Bouchama A, Shindo N, Al-Khairy K, Carson G, Taha Y, Sadat M, Alahmadi M. Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerg Infect Dis. 2016 Sep;22(9):1554-61. doi: 10.3201/eid2209.151164.</citation>
    <PMID>27532807</PMID>
  </reference>
  <reference>
    <citation>Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, Baker S, Nicol S, Conton B, Johnson W, Abiri OT, Kargbo O, Kamara P, Goba A, Russell JB, Gevao SM. Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect. 2017 Mar;74(3):302-309. doi: 10.1016/j.jinf.2016.11.009. Epub 2016 Nov 17.</citation>
    <PMID>27867062</PMID>
  </reference>
  <reference>
    <citation>Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.</citation>
    <PMID>32253318</PMID>
  </reference>
  <reference>
    <citation>Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.</citation>
    <PMID>32219428</PMID>
  </reference>
  <reference>
    <citation>Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, He L, Chen Y, Wu J, Shi Z, Zhou Y, Du L, Li F. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J Virol. 2020 Feb 14;94(5). pii: e02015-19. doi: 10.1128/JVI.02015-19. Print 2020 Feb 14.</citation>
    <PMID>31826992</PMID>
  </reference>
  <reference>
    <citation>Crowe JE Jr, Firestone CY, Murphy BR. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol. 2001 Oct 1;167(7):3910-8.</citation>
    <PMID>11564809</PMID>
  </reference>
  <reference>
    <citation>van Griensven J, Edwards T, Gallian P; Ebola-Tx Consortium. Convalescent Plasma for Ebola Virus Disease. N Engl J Med. 2016 Jun 23;374(25):2500. doi: 10.1056/NEJMc1602284.</citation>
    <PMID>27332913</PMID>
  </reference>
  <reference>
    <citation>Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, Chen Q, Zhang L, Zhong Q, Zhang X, Zou Y, Zhang S. Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest. 2020 Jul;158(1):e9-e13. doi: 10.1016/j.chest.2020.03.039. Epub 2020 Mar 31.</citation>
    <PMID>32243945</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Kashif Khan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Anti-SARS-CoV-2 plasma</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

